샘플 요청 목록

 카트 문의
시장보고서
상품코드
1869836

폴리데옥시리보뉴클레오티드(PDRN) 주사제 시장 규모, 점유율 및 동향 분석 보고서 : 제품별, 재료별, 용도별, 최종 용도별, 지역별, 부문 예측(2025-2033년)

Polydeoxyribonucleotide Injectables Market Size, Share & Trends Analysis Report By Product (Single-Ingredient Injectables, Combination Injectables), By Material, By Application, By End Use, By Region, And Segment Forecasts, 2025 - 2033
발행일: | 리서치사: Grand View Research | 페이지 정보: 영문 140 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

폴리데옥시리보뉴클레오티드(PDRN) 주사제 시장 요약

세계의 폴리데옥시리보뉴클레오티드(PDRN) 주사제 시장 규모는 2024년에 2억 1,137만 달러로 평가되었고, 2033년까지 8억 355만 달러에 이를 것으로 예측됩니다.

2025년부터 2033년까지의 CAGR은 16.2%를 나타낼 것으로 전망됩니다. 이 성장은 미용 치료에 대한 인지도 향상, 기술 진보 및 낮은 침습 요법으로의 전환으로 인한 것입니다.

또한, 폴리데옥시리보뉴클레오티드(PDRN)와 히알루론산(HA), 필수 비타민을 조합한 첨단 제제를 포함한 혁신적인 PDRN 주사제의 도입이 진행되고 있습니다. 이러한 혁신에 의해 PDRN의 재생·젊어짐 특성이 향상되어, 보다 폭넓은 피부 트러블에 대응 가능하게 되어, 환자님의 치료 효과가 향상하고 있습니다.

복합형 PDRN 주사제는 단체로 복수의 피부 트러블에 대응할 수 있기 때문에 급속하게 널리 받아들여지고 있습니다. 예를 들면, 프롤레늄사의 「VAMP」의 등장은 피부 재생 분야에 있어서 새로운 이정표라고 할 수 있습니다. 본제품은 PDRN에 비타민·아미노산·미네랄을 배합한 영양 칵테일을 조합해, 피부의 탄력·보습력·질감을 완전히 새로운 차원으로 인도합니다. VAMP는 피부 톤에 새로운 활력을 주고, 모공의 축소, 주름의 개선을 도모해, 이미 데미지를 입은 피부에도 회춘의 기회를 제공합니다. 그 이름대로 미용 피부과학의 최첨단을 가는 제품입니다. Science Direct에 게재된 조사 논문에 따르면, 히알루론산-폴리데옥시리보뉴클레오티드(HA-PDRN) 가교 하이드로겔은 피부 재생에 있어서 매우 효율적인 수단입니다. 히알루론산의 카르복실기와 PDRN의 아미노기가 공유결합으로 결합한 하이드로겔은 히알루론산 단독 제제보다 생체적합성이 향상되어 보다 많은 콜라겐 생산을 촉진합니다. 이러한 연구는 PDRN과 HA를 결합함으로써 보다 안정적이고 효과적인 주사 치료법을 개발할 가능성이 매우 크다는 것을 보여줍니다.

PDRN 관련 항가령 효과는 특히 비외과적인 안면 회춘 수단을 요구하는 중고년층을 중심으로 주사제 시장을 크게 견인하고 있습니다. PDRN은 콜라겐 양 증가, 조직 수복, 피부 탄성 개선 작용에 의해 주름, 잔주름의 경감, 처짐 개선에 기여하는 것으로 알려져 있습니다. PDRN이 손상된 조직을 복구하고 젊음의 외관을 실현하는 탁월한 효과는 효과적이고 장기적인 항 노화 솔루션을 찾는 사람들에게 매우 매력적입니다. 이러한 장점이 널리 인정됨에 따라 주사제 시장 수요는 앞으로도 계속 확대될 것입니다. 또한, 고령화가 진행되는 지역에서는 미용 치료에 대한 관심이 높아지고 있습니다.

또한 여드름에 대한 PDRN의 흉터 치유 특성이 시장 성장의 주요 요인이 되고 있습니다. PDRN 주사의 재생 의학적 측면은 여드름으로 인한 피부 문제에 대한 이상적인 솔루션입니다. PDRN은 세포 재생과 조직 복구를 활성화하여 여드름 흔적의 농도를 줄이고 피부 표면을 개선합니다. 그 결과, 안전하고 비외과적인 방법으로 피부 트러블을 해결하고 싶은 젊은층부터 성숙층의 환자 양쪽에, PDRN을 기반으로 한 치료가 점점 인기를 모으고 있어 이것이 미용 피부과에 있어서 PDRN 주사 도입 증가의 주인이 되고 있습니다.

자주 묻는 질문

  • 폴리데옥시리보뉴클레오타이드(PDRN) 주사제 시장 규모는 어떻게 예측되나요?
  • PDRN 주사제가 주목받는 이유는 무엇인가요?
  • PDRN 주사제가 중고년층에게 인기가 있는 이유는 무엇인가요?
  • PDRN 주사제가 여드름 흉터 치료에 어떻게 기여하나요?
  • PDRN 주사제의 주요 성분은 무엇인가요?
  • PDRN 주사제 시장의 주요 기업은 어디인가요?

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 폴리데옥시리보뉴클레오티드(PDRN) 주사제 시장의 변수, 동향, 범위

  • 시장 계통 전망
    • 상위 시장 전망
    • 관련/부수 시장 전망
  • 시장 역학
    • 시장 성장 촉진요인 분석
    • 시장 성장 억제요인 분석
  • 폴리데옥시리보뉴클레오티드(PDRN) 주사제 시장 분석 도구
    • 업계 분석 - Porter's Five Forces 분석
    • PESTEL 분석

제4장 폴리데옥시리보뉴클레오티드(PDRN) 주사제 시장 : 제품별 추정 및 동향 분석

  • 부문 대시보드
  • 폴리데옥시리보뉴클레오티드(PDRN) 주사제 시장 : 제품별 변동 분석
  • 폴리데옥시리보뉴클레오티드(PDRN) 주사제 시장 : 제품별 전망
  • 시장 규모와 예측 및 동향 분석(2021-2033년)
  • 단일 성분 주사제
  • 복합 주사제

제5장 폴리데옥시리보뉴클레오티드(PDRN) 주사제 시장 : 재료별 추정 및 동향 분석

  • 부문 대시보드
  • 폴리데옥시리보뉴클레오티드(PDRN) 주사제 시장 : 재료별 변동 분석
  • 폴리데옥시리보뉴클레오티드(PDRN) 주사제 시장 : 재료별 전망
  • 시장 규모와 예측 및 동향 분석(2021-2033년)
  • 연어 DNA 유래 폴리데옥시리보뉴클레오티드(PDRN)
  • 합성/재조합 폴리데옥시리보뉴클레오티드(PDRN)

제6장 폴리데옥시리보뉴클레오티드(PDRN) 주사제 시장 : 용도별 추정 및 동향 분석

  • 부문 대시보드
  • 폴리데옥시리보뉴클레오티드(PDRN) 주사제 시장 : 용도별 변동 분석
  • 폴리데옥시리보뉴클레오티드(PDRN) 주사제 시장 : 용도별 전망
  • 시장 규모와 예측 및 동향 분석(2021-2033년)
  • 미용
  • 피부 회복 및 재생
  • 수분 공급 및 질감 개선
  • 색소 침착 장애
  • 기타

제7장 폴리데옥시리보뉴클레오티드(PDRN) 주사제 시장 : 최종 용도별 추정 및 동향 분석

  • 부문 대시보드
  • 폴리데옥시리보뉴클레오티드(PDRN) 주사제 시장 : 최종 용도별 변동 분석
  • 폴리데옥시리보뉴클레오티드(PDRN) 주사제 시장 : 최종 용도별 전망
  • 시장 규모와 예측 및 동향 분석(2021-2033년)
  • 메드 스파
  • 피부과 클리닉
  • 병원

제8장 폴리데옥시리보뉴클레오티드(PDRN) 주사제 시장 : 지역별 추정 및 동향 분석

  • 지역 대시보드
  • 폴리데옥시리보뉴클레오티드(PDRN) 주사제 시장 : 지역별 변동 분석
  • 폴리데옥시리보뉴클레오티드(PDRN) 주사제 시장 : 지역별 추정 및 동향 분석
  • 시장 규모와 예측 및 동향 분석(2021-2033년)
  • 북미
    • 미국
    • 캐나다
    • 멕시코
    • 유럽
    • 영국
    • 독일
    • 프랑스
    • 이탈리아
    • 스페인
    • 덴마크
    • 스웨덴
    • 노르웨이
  • 아시아태평양
    • 일본
    • 중국
    • 인도
    • 한국
    • 호주
    • 태국
  • 라틴아메리카
    • 브라질
    • 아르헨티나
  • 중동 및 아프리카
    • 남아프리카
    • 사우디아라비아
    • 아랍에미리트(UAE)
    • 쿠웨이트

제9장 경쟁 구도

  • 시장 진출기업의 분류
  • 주요 기업 프로파일
    • ZK MEDIGROUP CO. LTD.
    • BioPlus Co., Ltd.
    • PharmaResearch Products Co. Ltd.
    • K-PrivateLabel
    • TY Cosmetic
    • Dermax Co., Ltd.
    • OTESALY
    • Singderm
    • Placentex
    • Zerone Cellvane
KTH 25.12.11

Polydeoxyribonucleotide Injectables Market Summary

The global polydeoxyribonucleotide injectables market size was estimated at USD 211.37 million in 2024 and is projected to reach USD 803.55 million by 2033, growing at a CAGR of 16.2% from 2025 to 2033. This growth is driven by increasing awareness of aesthetic treatments, technological advancements, and a move towards minimally invasive therapies.

Moreover, the introduction of innovative PDRN injectables, including advanced formulations that combine polydeoxyribonucleotides (PDRN) with hyaluronic acid (HA) and essential vitamins. These innovations improve the regenerative and rejuvenating properties of PDRN, addressing a wider range of skin issues and enhancing patient results.

Combination PDRN injectables are quickly gaining widespread acceptance because they can single-handedly address multiple skin problems. To illustrate, the debut of VAMP by Prollenium represents a new milestone in skin revitalization. The product pairs PDRN with a nutrient cocktail of vitamins, amino acids, and minerals to deliver skin firmness, hydration, and quality at a whole new level. VAMP sets out to breathe new life into the skin tone, shrink pore sizes, and wrinkle-free, and give the already compromised skin a chance to rejuvenate; therefore, it is on the cutting edge of aesthetic dermatology as its name suggests. According to a research article published by Science Direct, hyaluronic acid-polydeoxyribonucleotide (HA-PDRN) cross-linked hydrogels are a very efficient means of skin regeneration. The hydrogels made by the covalent bonding of carboxyl groups of Hyaluronic Acid to amino groups of PDRN show enhanced biocompatibility and more collagen production than those made solely from Hyaluronic Acid. These studies indicate the immense possibilities of developing more stable and effective injectable treatments by combining PDRN and HA.

PDRN-related anti-aging advantages greatly boost the injectable market, particularly for those middle-aged to older individuals looking for non-surgical means of facial rejuvenation. PDRN is known to increase collagen levels, repair tissue, and improve skin elasticity, leading to decreased wrinkles, fine lines, and sagging skin in general. PDRN's great benefit of repairing damaged tissues to achieve a younger appearance is extraordinarily attractive for those looking for effective, long-term anti-aging solutions. As people become more familiar with these benefits, the injectable market will continue to grow in demand. Moreover, there is an increased interest in aesthetic treatments in regions with an aging population.

In addition, the scar-healing property of PDRN for acne is becoming a major factor in market growth. The regenerative aspects of PDRN injections are a perfect solution for the skin problems caused by acne. PDRN can reduce the concentration of acne scars and improve the skin surface by activating cell regeneration and tissue repair. As a result, treatments based on PDRN are getting increasingly popular with both young and mature patients who want to solve their skin problems in a safe, non-surgical way, thus being the main factor in the increasing installation of PDRN injections in aesthetic dermatology.

Global Polydeoxyribonucleotide Injectables Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global polydeoxyribonucleotide injectables market report based on product, material, application, end use, and region:

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Single-Ingredient Injectable
  • Combination Injectable
  • Material Outlook (Revenue, USD Million, 2021 - 2033)
  • Salmon DNA-derived Polydeoxyribonucleotide (PDRN)
  • Synthetic/Recombinant Polydeoxyribonucleotide (PDRN)
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Aesthetics
  • Skin Repair & Regeneration
  • Hydration & Texture Improvement
  • Pigmentation Disorder
  • Others
  • by End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • MedSpas
  • Dermatology Clinics
  • Hospitals
  • Region Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.1. Segment Definitions
    • 1.1.1. Product
    • 1.1.2. Material
    • 1.1.3. Application
    • 1.1.4. End Use
    • 1.1.5. Regional scope
    • 1.1.6. Estimates and forecasts timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
      • 1.3.5.1. Data for primary interviews in North America
      • 1.3.5.2. Data for primary interviews in Europe
      • 1.3.5.3. Data for primary interviews in Asia Pacific
      • 1.3.5.4. Data for primary interviews in Latin America
      • 1.3.5.5. Data for Primary interviews in MEA
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.2. Approach 1: Commodity flow approach
    • 1.6.3. Volume price analysis (Model 2)
    • 1.6.4. Approach 2: Volume price analysis
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Material outlook
    • 2.2.3. Application outlook
    • 2.2.4. End use outlook
    • 2.2.5. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Polydeoxyribonucleotide (PDRN) Injectables Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Innovative Polydeoxyribonucleotide (PDRN) Injectables
      • 3.2.1.2. Antiaging Benefits of Polydeoxyribonucleotide (PDRN) Injectables
      • 3.2.1.3. Acne Scare healing property
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High Treatment cost
      • 3.2.2.2. Low Awareness
  • 3.3. Polydeoxyribonucleotide (PDRN) Injectables Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape

Chapter 4. Polydeoxyribonucleotide (PDRN) Injectables Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Polydeoxyribonucleotide (PDRN) Injectables Market: Product Movement Analysis
  • 4.3. Polydeoxyribonucleotide (PDRN) Injectables Market by Product Outlook (USD Million)
  • 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 4.5. Single-Ingredient Injectable
    • 4.5.1. Single-Ingredient Injectable Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Combination Injectable
    • 4.6.1. Combination Injectable Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Polydeoxyribonucleotide (PDRN) Injectables Market: Material Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Polydeoxyribonucleotide (PDRN) Injectables Market: Material Movement Analysis
  • 5.3. Polydeoxyribonucleotide (PDRN) Injectables Market by Material Outlook (USD Million)
  • 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 5.5. Salmon DNA- derived Polydeoxyribonucleotide (PDRN)
    • 5.5.1. Salmon DNA-derived Polydeoxyribonucleotide (PDRN) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Synthetic/Recombinant Polydeoxyribonucleotide (PDRN)
    • 5.6.1. Synthetic/Recombinant Polydeoxyribonucleotide (PDRN) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Polydeoxyribonucleotide (PDRN) Injectables Market: Application Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Polydeoxyribonucleotide (PDRN) Injectables Market: Application Movement Analysis
  • 6.3. Polydeoxyribonucleotide (PDRN) Injectables Market by Application Outlook (USD Million)
  • 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 6.5. Aesthetics
    • 6.5.1. Aesthetics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Skin Repair & Regeneration
    • 6.6.1. Skin Repair & Regeneration Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Hydration & Texture Improvement
    • 6.7.1. Hydration & Texture Improvement Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Pigmentation Disorder
    • 6.8.1. Pigmentation Disorder Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.9. Others
    • 6.9.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Polydeoxyribonucleotide (PDRN) Injectables Market: End Use Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Polydeoxyribonucleotide (PDRN) Injectables Market: End Use Movement Analysis
  • 7.3. Polydeoxyribonucleotide (PDRN) Injectables Market by End Use Outlook (USD Million)
  • 7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 7.5. MedSpas
    • 7.5.1. MedSpas Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Dermatology Clinics
    • 7.6.1. Dermatology Clinics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. Hospitals
    • 7.7.1. Hospitals Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Polydeoxyribonucleotide (PDRN) Injectables Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Dashboard
  • 8.2. Regional Polydeoxyribonucleotide (PDRN) Injectables Market Movement Analysis
  • 8.3. Polydeoxyribonucleotide (PDRN) Injectables Market: Regional Estimates & Trend Analysis
  • 8.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 8.5. North America
    • 8.5.1. North America Polydeoxyribonucleotide (PDRN) Injectables Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.2. U.S.
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Competitive Scenario
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. Reimbursement scenario
      • 8.5.2.5. U.S. Polydeoxyribonucleotide (PDRN) Injectables Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.3. Canada
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Competitive Scenario
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Reimbursement scenario
      • 8.5.3.5. Canada Polydeoxyribonucleotide (PDRN) Injectables Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.4. Mexico
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Competitive Scenario
      • 8.5.4.3. Regulatory Framework
      • 8.5.4.4. Reimbursement scenario
      • 8.5.4.5. Mexico Polydeoxyribonucleotide (PDRN) Injectables Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.5. Europe
    • 8.5.6. Europe Polydeoxyribonucleotide (PDRN) Injectables Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.7. UK
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Competitive Scenario
      • 8.5.7.3. Regulatory Framework
      • 8.5.7.4. Reimbursement scenario
      • 8.5.7.5. UK Polydeoxyribonucleotide (PDRN) Injectables Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.8. Germany
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Competitive Scenario
      • 8.5.8.3. Regulatory Framework
      • 8.5.8.4. Reimbursement scenario
      • 8.5.8.5. Germany Polydeoxyribonucleotide (PDRN) Injectables Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.9. France
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Competitive Scenario
      • 8.5.9.3. Regulatory Framework
      • 8.5.9.4. Reimbursement scenario
      • 8.5.9.5. France Polydeoxyribonucleotide (PDRN) Injectables Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.10. Italy
      • 8.5.10.1. Key Country Dynamics
      • 8.5.10.2. Competitive Scenario
      • 8.5.10.3. Regulatory Framework
      • 8.5.10.4. Reimbursement scenario
      • 8.5.10.5. Italy Polydeoxyribonucleotide (PDRN) Injectables Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.11. Spain
      • 8.5.11.1. Key Country Dynamics
      • 8.5.11.2. Competitive Scenario
      • 8.5.11.3. Regulatory Framework
      • 8.5.11.4. Reimbursement scenario
      • 8.5.11.5. Spain Polydeoxyribonucleotide (PDRN) Injectables Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.12. Denmark
      • 8.5.12.1. Key Country Dynamics
      • 8.5.12.2. Competitive Scenario
      • 8.5.12.3. Regulatory Framework
      • 8.5.12.4. Reimbursement scenario
      • 8.5.12.5. Denmark Polydeoxyribonucleotide (PDRN) Injectables Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.13. Sweden
      • 8.5.13.1. Key Country Dynamics
      • 8.5.13.2. Competitive Scenario
      • 8.5.13.3. Regulatory Framework
      • 8.5.13.4. Reimbursement scenario
      • 8.5.13.5. Sweden Polydeoxyribonucleotide (PDRN) Injectables Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.14. Norway
      • 8.5.14.1. Key Country Dynamics
      • 8.5.14.2. Competitive Scenario
      • 8.5.14.3. Regulatory Framework
      • 8.5.14.4. Reimbursement scenario
      • 8.5.14.5. Norway Polydeoxyribonucleotide (PDRN) Injectables Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Polydeoxyribonucleotide (PDRN) Injectables Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Competitive Scenario
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Reimbursement scenario
      • 8.6.2.5. Japan Polydeoxyribonucleotide (PDRN) Injectables Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Competitive Scenario
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. Reimbursement scenario
      • 8.6.3.5. China Polydeoxyribonucleotide (PDRN) Injectables Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Competitive Scenario
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. Reimbursement scenario
      • 8.6.4.5. India Polydeoxyribonucleotide (PDRN) Injectables Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.5. South Korea
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Competitive Scenario
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Reimbursement scenario
      • 8.6.5.5. South Korea Polydeoxyribonucleotide (PDRN) Injectables Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.6. Australia
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Competitive Scenario
      • 8.6.6.3. Regulatory Framework
      • 8.6.6.4. Reimbursement scenario
      • 8.6.6.5. Australia Polydeoxyribonucleotide (PDRN) Injectables Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.7. Thailand
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Competitive Scenario
      • 8.6.7.3. Regulatory Framework
      • 8.6.7.4. Reimbursement scenario
      • 8.6.7.5. Thailand Polydeoxyribonucleotide (PDRN) Injectables Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Latin America Polydeoxyribonucleotide (PDRN) Injectables Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Competitive Scenario
      • 8.7.2.3. Regulatory Framework
      • 8.7.2.4. Reimbursement scenario
      • 8.7.2.5. Brazil Polydeoxyribonucleotide (PDRN) Injectables Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Competitive Scenario
      • 8.7.3.3. Regulatory Framework
      • 8.7.3.4. Reimbursement scenario
      • 8.7.3.5. Argentina Polydeoxyribonucleotide (PDRN) Injectables Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8. Middle East & Africa
    • 8.8.1. Middle East & Africa Polydeoxyribonucleotide (PDRN) Injectables Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Competitive Scenario
      • 8.8.2.3. Regulatory Framework
      • 8.8.2.4. Reimbursement scenario
      • 8.8.2.5. South Africa Polydeoxyribonucleotide (PDRN) Injectables Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Competitive Scenario
      • 8.8.3.3. Regulatory Framework
      • 8.8.3.4. Reimbursement scenario
      • 8.8.3.5. Saudi Arabia Polydeoxyribonucleotide (PDRN) Injectables Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Competitive Scenario
      • 8.8.4.3. Regulatory Framework
      • 8.8.4.4. Reimbursement scenario
      • 8.8.4.5. UAE Polydeoxyribonucleotide (PDRN) Injectables Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Competitive Scenario
      • 8.8.5.3. Regulatory Framework
      • 8.8.5.4. Reimbursement scenario
      • 8.8.5.5. Kuwait Polydeoxyribonucleotide (PDRN) Injectables Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Market Participant Categorization
  • 9.2. Key Company Profiles
    • 9.2.1. ZK MEDIGROUP CO. LTD.
      • 9.2.1.1. Company overview
      • 9.2.1.2. Financial performance
      • 9.2.1.3. Product benchmarking
      • 9.2.1.4. Strategic initiatives
    • 9.2.2. BioPlus Co., Ltd.
      • 9.2.2.1. Company overview
      • 9.2.2.2. Financial performance
      • 9.2.2.3. Product benchmarking
      • 9.2.2.4. Strategic initiatives
    • 9.2.3. PharmaResearch Products Co. Ltd.
      • 9.2.3.1. Company overview
      • 9.2.3.2. Financial performance
      • 9.2.3.3. Product benchmarking
      • 9.2.3.4. Strategic initiatives
    • 9.2.4. K-PrivateLabel
      • 9.2.4.1. Company overview
      • 9.2.4.2. Financial performance
      • 9.2.4.3. Product benchmarking
      • 9.2.4.4. Strategic initiatives
    • 9.2.5. TY Cosmetic
      • 9.2.5.1. Company overview
      • 9.2.5.2. Financial performance
      • 9.2.5.3. Product benchmarking
      • 9.2.5.4. Strategic initiatives
    • 9.2.6. Dermax Co., Ltd.
      • 9.2.6.1. Company overview
      • 9.2.6.2. Financial performance
      • 9.2.6.3. Product benchmarking
      • 9.2.6.4. Strategic initiatives
    • 9.2.7. OTESALY
      • 9.2.7.1. Company overview
      • 9.2.7.2. Financial performance
      • 9.2.7.3. Product benchmarking
      • 9.2.7.4. Strategic initiatives
    • 9.2.8. Singderm
      • 9.2.8.1. Company overview
      • 9.2.8.2. Financial performance
      • 9.2.8.3. Product benchmarking
      • 9.2.8.4. Strategic initiatives
    • 9.2.9. Placentex
      • 9.2.9.1. Company overview
      • 9.2.9.2. Financial performance
      • 9.2.9.3. Product benchmarking
      • 9.2.9.4. Strategic initiatives
    • 9.2.10. Zerone Cellvane
      • 9.2.10.1. Company overview
      • 9.2.10.2. Financial performance
      • 9.2.10.3. Product benchmarking
      • 9.2.10.4. Strategic initiatives
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제